An Effective Adjuvant Therapy In Treatment Of Anemic Hemodialysis Patient With Hypozencemia: A review article

Main Article Content

Marwan Ahmed Shehata, AL Sayed Ahmed AL Nahal; Abeer Abdalla Fikry; Medhat Ibrahim Mahmoud

Keywords

Hypozencemia; Hemodialysis Patients; Anemia; Zinc Supplementation

Abstract

Anemia of chronic renal disease is of multifactorial origin, the widely accepted etiology being decreased renal production of erythropoietin (EPO), the hormone responsible for stimulating red blood cell production. Decreased erythropoietin has recently been linked with the downregulation of hypoxia-inducible factor (HIF), a transcription factor that regulates gene expression of erythropoietin. Other mechanisms include uremia (leading to RBC deformity responsible for hemolysis), folate and vitamin B12 deficiency, iron deficiency, bleeding due to dysfunctional platelets, and rarely blood loss from hemodialysis.Treatment of end-stage renal disease involves correcting parameters at the level of the patient's presentation Interventions aimed at slowing the rate of kidney disease. Zinc is one of the most valuable trace elements in the body, and the symptoms caused by zinc deficiency may not be limited to anemia but may also include systemic symptoms, such as hair loss, dermatitis, and dysgeusia. Zinc deficiency is also an important cause of renal anemia in CKD, but reports on this are scarce. However, anemia is very common in CHF. The aim of this article to review an effective adjuvant therapy in treatment of anemic hemodialysis patient with hypozencemia.

Abstract 42 | PDF Downloads 23

References

1- Acosta-Ochoa, I., Bustamante-Munguira, J., Mendiluce-Herrero, A., Bustamante-Bustamante, J., & Coca-Rojo, A. (2019). Impact on Outcomes across KDIGO-2012 AKI Criteria According to Baseline Renal Function. Journal of Clinical Medicine, 8(9).
2- Ahmed, A., clinics, R. C.-H. failure, & 2008, undefined. (n.d.). Epidemiology of chronic kidney disease in heart failure. Elsevier. Retrieved May 5, 2023, from https://www.sciencedirect.com/science/article/pii/S1551713608000470.
3- Bello, N. A., Lewis, E. F., Desai, A. S., Anand, I. S., Krum, H., McMurray, J. J. V., Olson, K., Solomon, S. D., Swedberg, K., Van Veldhuisen, D. J., Young, J. B., & Pfeffer, M. A. (2015). Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. European Journal of Heart Failure, 17(11), 1201–1207.
4- Cramer, M. T., & Guay-Woodford, L. M. (2015). Cystic Kidney Disease: A Primer. Advances in Chronic Kidney Disease, 22(4), 297–305. https://doi.org/10.1053/j.ackd.2015.04.001
5- Crews, D. C., & Novick, T. K. (2020). Achieving equity in dialysis care and outcomes: The role of policies. Seminars in Dialysis, 33(1), 43–51.
6- Amdur, R., Feldman, H., Gupta, J., … W. Y.-C. journal of the, & 2016, undefined. (n.d.). Inflammation and progression of CKD: the CRIC study. Am Soc Nephrol. Retrieved May 6, 2023, from https://cjasn.asnjournals.org/content/11/9/1546.short
7- El-Arbagy, A. R., Yassin, Y. S., & Boshra, B. N. (2016). Study of prevalence of end-stage renal disease in Assiut governorate, upper Egypt. Menoufia Medical Journal, 29(2), 222. https://doi.org/10.4103/1110-2098.192441.
8- Amenós, A., López, R., Edition), J. P.-N. (English, & 2017, undefined. (n.d.). Heart failure in patients with kidney disease and iron deficiency: The role of iron therapy. Elsevier. Retrieved 2023, from https://www.sciencedirect.com/ science/article/pii/ S20132 51417301931.
9- Batista, M. N., Cuppari, L., De Fátima Campos Pedrosa, L., Almeida, M. D. G., De Almeida, J. B., De Medeiros, A. C. Q., & Canziani, M. E. F. (2006). Effect of end-stage renal disease and diabetes on zinc and copper status. Biological Trace Element Research, 112(1), 1–12.
10- Francis, A., Johnson, D. W., Melk, A., Foster, B. J., Blazek, K., Craig, J. C., & Wong, G. (2020). Survival after kidney transplantation during childhood and adolescence. Clinical Journal of the American Society of Nephrology, 15(3), 392–400.
11- Barratt, J., Andric, B., Tataradze, A., Schömig, M., Reusch, M., Valluri, U., & Mariat, C. (2021). Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 36(9), 1616–1628.
12- Portolés, J., Martín, L., Broseta, J. J., & Cases, A. (2021a). Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Frontiers in Medicine, 8, 328.
13- Provenzano, R., Shutov, E., Eremeeva, L., Korneyeva, S., Poole, L., Saha, G., Bradley, C., Eyassu, M., Besarab, A., Leong, R., Liu, C. S., Neff, T. B., Szczech, L., & Yu, K. H. P. (2021). Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 36(9), 1717–1730.
14- Portolés, J., Martín, L., Broseta, J. J., & Cases, A. (2021b). Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Frontiers in Medicine, 8, 328. https://doi.org/10.3389/FMED.2021.642296/BIBTEX
15- Portolés, J., Martín, L., Broseta, J. J., & Cases, A. (2021c). Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Frontiers in Medicine, 8, 328. https://doi.org/10.3389/FMED.2021.642296/BIBTEX
16- Portolés, J., Martín, L., Broseta, J. J., & Cases, A. (2023). Anemia Of Chronic Renal Disease. Frontiers in Medicine, 8. https://doi.org/10.3389/FMED.2021.642296/FULL
17- Azeem, Z., Emanuel, A., Malhotra, K., Azeem, Z., Emanuel, • A, Malhotra, K, & Nolph, K. D. (2022a). Continuous Renal Replacement Therapy. Procedures and Protocols in the Neurocritical Care Unit, 649–678.
18- Azeem, Z., Emanuel, A., Malhotra, K., Azeem, Z., Emanuel, • A, Malhotra, • K, & Nolph, K. D. (2022b). Continuous Renal Replacement Therapy. Procedures and Protocols in the Neurocritical Care Unit, 649–678.
19- Al-Timimi, D.J.; Sulieman, D.M.; Hussen, K.R. Zinc status in type 2 diabetic patients: Relation to the progression of diabetic nephropathy. J. Clin. Diagn. Res. 2014, 8, 4–8.
20- Rostoker, G., Loridon, C., Griuncelli, M., EBioMedicine, C. R.-, & 2019, undefined. (n.d.). Liver iron load influences hepatic fat fraction in end-stage renal disease patients on dialysis: a proof of concept study. Elsevier. Retrieved May 5, 2023, from https://www.sciencedirect.com/science/article/pii/S2352396418305139
21- Rottembourg, J., Kadri, A., … E. L.-N. D., & 2011, undefined. (n.d.). Do two intravenous iron sucrose preparations have the same efficacy? Academic.Oup.Com. Retrieved May 5, 2023, from https://academic.oup.com/ndt/article-abstract/26/10/3262/1902153
22- Sexton, D. J., Reule, S., & Foley, R. N. (2017). End-Stage Kidney Disease From Scleroderma in the United States, 1996 to 2012. Kidney International Reports, 3(1), 148–154. https://doi.org/10.1016/J.EKIR.2017.09.003
23- Sgroi, M. D., Kirkpatrick, V. E., Resnick, K. A., Williams, R. A., Wilson, S. E., & Gordon, I. L. (2015). Less Than Total Excision of Infected Prosthetic PTFE Graft Does Not Increase the Risk of Reinfection. Http://Dx.Doi.Org/10.1177/1538574415583849, 49(1–2), 12–15.
24- Shaikh, N., Chanda, A., Ganaw, A., Sameer, M., Hassan, J., Farooqi, W., Mohsin, M., & Haji, A. M. (2022). Vascular Access: From Cannulation to Decannulation. Improving Anesthesia Technical Staff’s Skills, 171–195. https://doi.org/10.1007/978-3-030-88849-7_12
25- Son, H. E., Ryu, J. Y., Go, S., Yi, Y., Kim, K., Oh, Y. K., Oh, K. H., & Chin, H. J. (2020). Association of ambulatory blood pressure monitoring with renal outcome in patients with chronic kidney disease. Kidney Research and Clinical Practice, 39(1), 70–80. https://doi.org/10.23876/J.KRCP.19.103
26- Peter, W. L., Guo, H., Kabadi, S., Gilbertson, D. T., Peng, Y., Pendergraft, T., & Li, S. (2018). Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. BMC Nephrology, 19(1).
27- Sweet, M. A., Cumpston, A., Briggs, F., Craig, M., & Hamadani, M. (2012). Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line–associated bloodstream infections and contamination of blood cultures in an inpatient oncology unit. American Journal of Infection Control, 40(10), 931–934.
28- Takahashi, A. (2022). Role of zinc and copper in erythropoiesis in patients on hemodialysis. Journal of Renal Nutrition, 32(6), 650-657.
29- Umanath, K., Jalal, D., … B. G.-J. of the, & 2015, undefined. (n.d.). Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. Am Soc Nephrol. Retrieved 2023, from https://jasn.asnjournals.org/content/26/10/2578.short
30- Wakasugi, M., & Narita, I. (2022). Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006–2020. Nephrology. https://doi.org/10.1111/NEP.14134
31- Yaldizli, Ö., Johansson, U., Gizewski, E. R., & Maschke, M. (2006). Copper deficiency myelopathy induced by repetitive parenteral zinc supplementation during chronic hemodialysis [3]. Journal of Neurology, 253(11), 1507–1509.
32- Takahashi, A. (2022). Role of Zinc and Copper in Erythropoiesis in Patients on Hemodialysis. Journal of Renal Nutrition, 32(6), 650–657.
33- Sato, E., Sato, S., Degawa, M., Ono, T., Lu, H., Matsumura, D., ... & Nakamura, T. (2022). Effects of Zinc Acetate Hydrate Supplementation on Renal Anemia with Hypozincemia in Hemodialysis Patients. Toxins, 14(11), 746.
34- Olechnowicz, J., Tinkov, A., Skalny, A., & Suliburska, J. (2018). Zinc status is associated with inflammation, oxidative stress, lipid, and glucose metabolism. The Journal of Physiological Sciences : JPS, 68(1), 19–31. https://doi.org/10.1007/S12576-017-0571-7
35- Natchu, U. C. M., Fataki, M. R., & Fawzi, W. W. (2008). Zinc as an adjunct for childhood pneumonia - interpreting early results. Nutrition Reviews, 66(7), 398–405.
36- Matson, M. Wright, A. Oliver et al., “Zinc supplementation at conventional doses does not improve the disturbance of taste perception in hemodialysis patients,” Journal of Renal Nutrition, vol. 13, no. 3, pp. 224–228, 2003
37- Kobayashi, H., Abe, M., Okada, K., Tei, R., Maruyama, N., Kikuchi, F., ... & Soma, M. (2015). Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis. Nutrients, 7(5), 3783-3795.
38- Feng, H. L., Chen, Y. H., & Jeng, S. S. (2019). Effect of zinc supplementation on renal anemia in 5/6-nephrectomized rats and a comparison with treatment with recombinant human erythropoietin. International Journal of Molecular Sciences, 20(20).
39- Yildiz, A., Kaya, Y., Prevention, O. T.-J. of C., & 2019, undefined. (n.d.). Effect of the interaction between selenium and zinc on DNA repair in association with cancer prevention. Ncbi.Nlm.Nih.Gov. Retrieved 2023, from https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC6786808/